AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for…
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…